PubMed Health⌕ Search

PubMed · 15119492

Rectal function following permanent prostate brachytherapy.

Abstract

The purpose of this study was to review the clinical presentation, dosimetry, quality of life assessment, and management of proctitis following permanent prostate brachytherapy. The permanent prostate brachytherapy literature was reviewed using MEDLINE searches to ensure completeness. Rectal complications primarily consist of mild, self-limited proctitis. Rectal bleeding has been correlated with rectal dose. Dose response analysis has demonstrated that the risk of proctitis strongly correlates with the volume of rectal tissue exposed to a given dose. The reported incidence of rectal ulceration/fistula formation is < or = 1%. Constipation significantly increases the radiation dose to the rectum and potentially may contribute to brachytherapy-related morbidity. Quality of life assessments obtained via patient-administered instruments and by physician interview have illustrated that long-term bowel dysfunction is relatively uncommon. Significant bowel dysfunction following prostate brachytherapy is relatively rare, but rectal bleeding has been correlated with radiation dose. Routine post-brachytherapy biopsies of the anterior rectal wall are strongly contraindicated. The continued elucidation of the etiology of bowel dysfunction should result in refinements in implant technique and decreased brachytherapy-related morbidity.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gregory S Merrick, Wayne M Butler. Rectal function following permanent prostate brachytherapy.. https://pubmed.ncbi.nlm.nih.gov/15119492/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Dose errors due to inhomogeneities in balloon catheter brachytherapy for breast cancer.

PURPOSE: To evaluate dose errors in balloon catheter brachytherapy of breast cancer due to inhomogeneities, such as iodine-containing radiographic contrast medium in the balloon, the lack of scattering medium, and the low density of lung that are not considered by commercial treatment planning systems (TPS). METHODS AND MATERIALS: By accounting for these inhomogeneities in breast/lung phantoms, Monte Carlo simulations were performed to calculate doses in the breast and lung. Doses were also calculated by a commercial TPS. The Monte Carlo doses and the TPS doses were compared along the transverse and longitudinal axes of the source. RESULTS: The Monte Carlo doses were lower by 4-10% on the prescription line than the TPS doses, depending on the concentration (5-25% by volume) of the contrast medium, and on the direction from the source. The lack of scattering medium around the breast contributes to the differences more than the attenuation by the contrast medium. Attenuation contributed approximately 1.0-4.8% at the concentrations investigated in this study. CONCLUSIONS: Current treatment planning systems, which assume a source in a large homogeneous water-equivalent medium, significantly overestimate doses in breast brachytherapy.

Brachytherapy↗

Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis.

PURPOSE: To evaluate, in a retrospective review, prostate brachytherapy dosimetry outcomes relative to the transurethral resection of the prostate (TURP) cavity size to address the theoretical concern that an intraprostatic cavity may hinder adequate radioactive source placement. METHODS AND MATERIALS: A total of 73 patients who underwent prostate brachytherapy as part of their treatment of localized prostate cancer had a history of a prior TURP. Of these 73 patients, 37 underwent (125)I implantation, 19 (103)Pd implantation, and 17 partial (103)Pd implantation. The dose was calculated using the dose to 90% of the prostate gland (D(90)) from the 1-month post-implant dosimetric analysis. The doses were normalized relative to 100% of the prescription dose. Archived transrectal ultrasound images were used to determine the maximal length and width of the visible residual TURP cavities. The prolate spheroid or symmetric egg shape was used to calculate each residual cavity volume. The derived volume of the TURP cavity was divided by the measured ultrasound volume of the prostate at brachytherapy, creating a percentage of volume measurement for each prostate. All p values, unless otherwise specified, were generated by comparing patients without a visible TURP defect with the subgroups of patients with a visible defect using the Student t test. RESULTS: A visible residual TURP defect was noted on the operative transrectal ultrasound images of 55 (75%) of the 73 patients with a history of TURP before brachytherapy. The 18 patients without a visible TURP defect had a median D(90) of 96% and were used for subsequent statistical comparison. Thirty-six patients with a TURP defect <10% of the entire prostate volume had a median D(90) of 109% (p = 0.02). Thirteen patients with a TURP defect between 10% and 20% of the prostate volume had a median D(90) of 112% (p = 0.03). Six patients with a TURP defect >20% of the prostate volume had a D(90) of 89% (p = 0.43). CONCLUSION: A visible residual TURP cavity that is assumed to have a prolate spheroid shape and occupy >/=10% of a prostate volume did not appear to be a statistically significant hindrance to proper dosimetric outcome.

Brachytherapy↗